Ellenbecker Investment Group Trims Position in Pfizer Inc. (NYSE:PFE)

Ellenbecker Investment Group trimmed its stake in Pfizer Inc. (NYSE:PFE) by 16.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,703 shares of the biopharmaceutical company’s stock after selling 2,060 shares during the period. Ellenbecker Investment Group’s holdings in Pfizer were worth $284,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also added to or reduced their stakes in PFE. FNY Investment Advisers LLC boosted its holdings in shares of Pfizer by 110.7% in the fourth quarter. FNY Investment Advisers LLC now owns 13,464 shares of the biopharmaceutical company’s stock valued at $357,000 after purchasing an additional 7,075 shares during the period. BCS Wealth Management bought a new stake in Pfizer during the 4th quarter valued at $1,213,000. Sightline Wealth Advisors LLC lifted its holdings in shares of Pfizer by 28.6% in the 4th quarter. Sightline Wealth Advisors LLC now owns 15,134 shares of the biopharmaceutical company’s stock worth $402,000 after buying an additional 3,366 shares during the period. Pallas Capital Advisors LLC grew its position in shares of Pfizer by 487.5% during the 4th quarter. Pallas Capital Advisors LLC now owns 151,062 shares of the biopharmaceutical company’s stock worth $4,008,000 after buying an additional 125,351 shares in the last quarter. Finally, Miracle Mile Advisors LLC grew its position in shares of Pfizer by 11.2% during the 4th quarter. Miracle Mile Advisors LLC now owns 219,700 shares of the biopharmaceutical company’s stock worth $5,829,000 after buying an additional 22,097 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 0.3 %

Pfizer stock opened at $26.79 on Tuesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market cap of $151.82 billion, a PE ratio of 36.20, a price-to-earnings-growth ratio of 0.63 and a beta of 0.64. The stock has a 50-day moving average of $26.16 and a two-hundred day moving average of $28.04. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue was up 31.2% on a year-over-year basis. During the same period last year, the firm posted ($0.17) EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.42%. Pfizer’s payout ratio is 232.43%.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research reports. UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.